Amid a growing consumer demand for sleep, stress, mood, metabolic, and digestive health, ADM is showcasing its range of pre-, pro-, and postbiotics and pharmaceutical ingredients at the ongoing CPHI 2025 trade show (October 28–30). The company is also launching a new vegetable glycerin-based excipient for the pharma industry.
At the event in Frankfurt, Germany, Nutrition Insight sits down with Marie-Bénédicte Charpentier, marketing director and head of EMEA at ADM.
“We’re showcasing the breadth and depth of our science-backed health and wellness solutions portfolio for nutraceuticals and dietary supplements, along with our specialty oils, active pharmaceutical ingredients, and excipients tailored to the pharmaceutical industry.”
ADM is featuring its postbiotics suite to support dietary supplement brands in answering consumer calls for more solutions that target mental and emotional well-being, metabolic health, and gut health.
“Since postbiotics contain inanimate microorganisms, they can retain efficacy through tough formulation environments like high heat, which may otherwise damage conventional probiotics,” adds Charpentier.
“They can also survive throughout shelf life and do not require refrigeration, which are critical attributes in evolving the nutraceutical landscape with formats like gummies and stick packs.”
Pharmaceutical innovations
Moreover, ADM is launching a new ingredient in its pharma solutions portfolio — ADM Purified Glycerin LA — “an incredibly versatile excipient.”
“Purified Glycerin LA is helping unlock new horizons in pharmaceutical formulations. It is a premium vegetable glycerin that contains very low aldehydes (less than five ppm) and provides a cost benefit, making it purposefully designed to effectively replace synthetic glycerin in sensitive formulations,” details Carpentier.
.jpeg)
ADM is showcasing its range of pre-, pro-, and postbiotics and pharmaceutical ingredients at the CPHI 2025 trade show.The excipient complies with the Pharmacopeias’ requirements and is suitable for large-molecule formulations, supporting complex parenteral formulations.
“This launch builds upon our range of highly purified, vegetable-derived ingredients, which comply with major pharmaceutical standards and are produced under strict cGMP (current Good Manufacturing Practices) guidelines.”
Postbiotic advances
ADM showcases several postbiotics at CPHI 2025, including its newest postbiotic, Lactobacillus gasseri CP2305. Charpentier says this solution is a “game-changer” for products targeting highly sought-after aspects of wellness, including sleep, stress, and mood. “ADM research finds sleep is the top wellness area that European consumers wish to improve,” she details.
Charpentier highlights ADM’s robust clinical validation for the postbiotic with eight human clinical trials. “Research suggests that supplementing one’s diet with L. gasseri CP2305 postbiotic may support emotional well-being, may support reduced stress, and may be associated with better sleep efficiency, reduced time to fall asleep/sleep latency, healthy overall sleep quality, and improved total sleep duration.”
Moreover, she adds that specific data demonstrates that supplementing with L. gasseri CP2305 may support positive moods and reduce stress/anxiety in healthy young women (at an average age of 21.5) experiencing premenstrual symptoms.
“A second clinical study showed L. gasseri CP2305 postbiotic may support positive changes in physiological and emotional parameters in women experiencing menopause based on two validated questionnaires,” says Charpentier.
The postbiotic may also support reduced stress and occasional fatigue associated with exercise, improved stress levels and recovery from exercise in male athletes, and positive mitochondrial function.
Biotics for metabolism and digestion
Other postbiotics on display have “outstanding clinical research” for metabolic and digestive health, highlights Charpentier.
Marie-Bénédicte Charpentier, marketing director and head of EMEA at ADM.“Our BPL1 (Bifidobacterium animalis subsp. lactis CECT8145) postbiotic targets aspects relevant to metabolic health, and B. longum CECT7347 (ES1) may support overall gut and digestive health, in addition to the potential for supporting reduced bloating.”
“Secondary findings from the study on ES1 showed an improvement in the quality of life score compared to a placebo and a significant reduction in stress versus the placebo, as measured by the State-Trait Anxiety Index,” she continues. “This research emphasizes the importance of the gut microbiome in not only physical well-being, but also emotional well-being and quality of life.”
The company also highlights multi-strain probiotic blends and synbiotics for tailored support at CPHI. “For example, we can combine our pro- and postbiotics into one formulation with our ADM/Matsutani LLC’s Fibersol, a prebiotic dietary fiber, to further provide prebiotic support for the gut,” says Charpentier.
“With the inclusion of prebiotic fiber, we can support good bacteria in the gut, and through pro- and postbiotics, we can help modulate the microbiota for factors impacting both physical and mental well-being.”
Health benefits driving innovation
Charpentier says medical communities and consumers both drive innovation in nutraceuticals. For example, she observes increased needs for supportive solutions for allergies, as well as for skin health concerns like acne, and growing demand for life stage and lifestyle support.
“Our research indicates growing concerns from consumers about their stress levels and impact on sleep quality, and vice versa,” she adds. “This focus on sleep and stress management is valued by all generations, proving to be an extensive innovation area for supplement brands.”
“At the same time, we find that women are drawn to these solutions, along with a personalized approach for different life stages, from menstrual cycles to pregnancy and lactation to menopause,” says Charpentier. “Solutions like L. gasseri CP2305 are helping manufacturers provide innovation that meets women where they are on their wellness journeys and during their specific life stages.”
In addition, she notes the industry must provide solutions for the aging European population, helping consumers maintain a good quality of life and an active lifestyle for as long as possible.
Charpentier says ADM research indicates growing concerns from consumers about their stress levels and impact on sleep quality, and vice versa.“While the large segment of baby boomers, along with Gen X, are certainly focused on solutions with immediate health benefits, consumers in their 40s, 30s, and even 20s are also proactively seeking solutions they can incorporate into their routines now to support a healthy, active lifestyle today and for the decades ahead.”
Gut health support
Charpentier notes that solutions connecting the gut-organ axes, including for metabolic and muscle health, are significant in supporting consumers’ pursuit of prolonging a good quality of life.
“Additionally, consumer interest in digestive health-supporting solutions is not subsiding,” she underscores. “Consumers recognize the role their gut plays in various aspects of their well-being and that when they feel good in their gut, they also are more likely to feel good overall.”
“Digestive and gut health support is crucial in supporting one’s quality of life. Brands that leverage robust solutions with validated clinical results, like ES1 postbiotic, can help usher in the next wave of innovation within the supplement category and the greater health and wellness arena.”
Nutraceuticals meet pharma
ADM observes that more companies in the traditional pharmaceutical space are interested in exploring dietary supplements and nutraceuticals, and are building new consumer products.
“These companies may wish to have a direct line to the consumer, they may want to bring solutions to market faster, or they may be curious about the innovation possibilities with emerging research areas, such as with the gut microbiome,” says Charpentier.
“With a vast health and wellness solutions portfolio, including our science-backed postbiotics, ADM can help pharma companies launch their own dietary supplement lines,” she highlights. “These postbiotic strains can also support expanded opportunity within clinical nutrition because they can retain efficacy and stability in many formulation environments and throughout shelf life.”
Charpentier notes that sharing ongoing research into the modes of action of postbiotics with the pharma sector can help bridge the gap for pharma companies that may be curious about the nutraceutical space.
“We’re thrilled to be at CPHI having these discussions and demonstrating the potential ingredients like postbiotics can provide for pharma companies investigating new avenues within clinical nutrition and beyond.”
